Crew Capital Management Ltd. Sells 396 Shares of Bristol-Myers Squibb (NYSE:BMY)

Crew Capital Management Ltd. cut its holdings in Bristol-Myers Squibb (NYSE:BMY) by 7.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,195 shares of the biopharmaceutical company’s stock after selling 396 shares during the quarter. Crew Capital Management Ltd.’s holdings in Bristol-Myers Squibb were worth $267,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Altrius Capital Management Inc boosted its stake in shares of Bristol-Myers Squibb by 27.1% during the fourth quarter. Altrius Capital Management Inc now owns 68,832 shares of the biopharmaceutical company’s stock valued at $3,532,000 after purchasing an additional 14,690 shares in the last quarter. Adell Harriman & Carpenter Inc. boosted its position in Bristol-Myers Squibb by 11.9% during the 4th quarter. Adell Harriman & Carpenter Inc. now owns 5,870 shares of the biopharmaceutical company’s stock valued at $301,000 after acquiring an additional 625 shares in the last quarter. Mid American Wealth Advisory Group Inc. increased its holdings in shares of Bristol-Myers Squibb by 10.2% in the 4th quarter. Mid American Wealth Advisory Group Inc. now owns 83,155 shares of the biopharmaceutical company’s stock valued at $4,050,000 after acquiring an additional 7,688 shares during the period. Choreo LLC lifted its stake in shares of Bristol-Myers Squibb by 2.9% during the 4th quarter. Choreo LLC now owns 88,442 shares of the biopharmaceutical company’s stock worth $4,538,000 after purchasing an additional 2,492 shares during the last quarter. Finally, Mather Group LLC. boosted its position in Bristol-Myers Squibb by 7.1% during the fourth quarter. Mather Group LLC. now owns 25,721 shares of the biopharmaceutical company’s stock valued at $1,320,000 after purchasing an additional 1,696 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Redburn Atlantic lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price target for the stock from $77.00 to $54.00 in a report on Tuesday, February 6th. Wells Fargo & Company increased their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday, April 18th. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 15th. Finally, Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Stock Performance

Shares of NYSE:BMY traded down $0.21 during trading on Monday, hitting $44.64. 16,422,664 shares of the stock traded hands, compared to its average volume of 15,973,845. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The company has a fifty day moving average price of $51.03 and a two-hundred day moving average price of $51.10. Bristol-Myers Squibb has a 52-week low of $44.34 and a 52-week high of $69.10. The company has a market cap of $90.49 billion, a price-to-earnings ratio of -14.41, a P/E/G ratio of 15.47 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. During the same quarter last year, the business earned $2.05 earnings per share. The firm’s revenue was up 4.7% on a year-over-year basis. As a group, equities analysts predict that Bristol-Myers Squibb will post 0.58 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 5.38%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.